Article Information
History
- April 19, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Omar Nadeem1,*,#,
- Michelle P. Aranha1,4,*,
- Robert Redd2,
- Michael Timonian1,4,
- Sophie Magidson1,
- Elizabeth D. Lightbody1,4,
- Jean-Baptiste Alberge1,4,
- Luca Bertamini1,
- Ankit K. Dutta1,
- Habib El-Khoury1,
- Mark Bustoros1,3,
- Jacob P. Laubach1,
- Giada Bianchi1,
- Elizabeth O’Donnell1,
- Ting Wu4,
- Junko Tsuji4,
- Kenneth Anderson1,
- Gad Getz4,
- Lorenzo Trippa2,
- Paul G. Richardson1,
- Romanos Sklavenitis-Pistofidis1,4 and
- Irene M. Ghobrial1,#
- 1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- 2Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA
- 3Division of Hematology and Medical Oncology, Meyer Cancer Center, New York-Presbyterian Hospital, New York, New York, USA
- 4Broad Institute, Boston, MA, USA
- ↵#Corresponding Authors: Irene Ghobrial, MD, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, irene_ghobrial{at}dfci.harvard.edu, Phone: 617-632-4198, Omar Nadeem, MD, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, omar_nadeem{at}dfci.harvard.edu, Phone: 617-632-4952
Posted April 19, 2024.
Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone
